Mirvetuximab soravtansine improved overall survival, progression-free survival, second progression-free survival, and other outcomes.

Explore how U.S. tariffs and vaccine skepticism may impact GSK plc's profitability. Click for my update as tariffs are ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

When I’ve made mistakes on people, it’s usually for cultural reasons,” Walmsley told Norges Bank Investment Management CEO ...